SureTrader
Home > Boards > Free Zone > Health and Sciences > Biotech Values

The estimated patent date of Remicade and Rituxan

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
rwdm Member Profile
 
Followed By 3
Posts 98
Boards Moderated 0
Alias Born 07/19/10
160x600 placeholder
Yellen Flags Risks To Outlook That Could Delay Rate Rises
Federal Reserve Chairwoman Janet Yellen flagged risks to the economic outlook that could delay the central bank's plans for raising short-term interest rates, in her semiannual testimony to Congress on U.S. monetary policy.
More Top Equities Stories Of The Day
Star Wars' Is the Force Behind Strong Hasbro Sales -- Update
Andreessen Horowitz Sells Some Lyft Shares to Prince Al-Waleed
Peabody to Draw Down Rest of Revolving Loan
U.S. Judge Questions Regulators on MetLife Designation
Panel Recommends FDA Approval of Remicade Knockoff
Time Warner Sees Strong Subscriber Gains
Ex-J.P. Morgan Executive Fined $1 Million Over London Whale Trades -- Update
Anadarko Slashes Dividend By 81% -- 2nd Update
rwdm   Thursday, 07/29/10 02:07:10 PM
Re: None
Post # of 199651 
The estimated patent date of Remicade and Rituxan in Europe are 2014 and 2015 respectively. In the US both expiry dates are in 2018. Is this because of Genentech's Cabily patent? If yes, does this mean that the expiry date of most of the mabs in US is 2018?

Is Teva's Rituximab TL011, which is starting nowadays clinical trials, in the regulatory pathway of BLA or as a biosimilar?

SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist